What question did this study set out to answer?

Evaluate the effects of combined targeting of mesothelin and tenascin-C on CAR-T cell function and tumor microenvironment in ovarian cancer.

June 11, 2026Molecular ImmunologyOpen Access

Combined targeting of mesothelin and tenascin-C enhances CAR-T cell function and tumor microenvironment modulation in ovarian cancer

View Full Paper

Ask AI

Bookmark

Evaluate the effects of combined targeting of mesothelin and tenascin-C on CAR-T cell function and tumor microenvironment in ovarian cancer.
Generated CAR-T cells targeting mesothelin and tenascin-C using lentiviral vectors.
Conducted functional assays including cytokine release, cytotoxicity, and immune synapse quantification.
Performed in vivo xenograft studies with randomized treatment allocation and blinded measurements.
Dual-target CAR-T cells showed enhanced NFAT activation and increased cytokine secretion compared to single-target controls.
In vivo experiments demonstrated delayed tumor growth and increased T cell infiltration.
Combination targeting reduced extracellular matrix deposition and improved CAR-T cell persistence.

No takes yet. Share an insight, caveat, or question.

Randomized trial demonstrates improved CAR-T cell activation in ovarian cancer with dual-targeting approach, suggesting enhanced therapy potential.

Wang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial demonstrates improved CAR-T cell activation in ovarian cancer with dual-targeting approach, suggesting enhanced therapy potential.